Uzun Ozcan, Heybeli Cihan, Kutlu Fatma Sema Anar, Celebioglu Pekiner Manolya, Yıldırım Filiz, Cavdar Caner, Sarioglu Sulen
Yalova Research and Training Hospital, Yalova, Turkey.
Division of Nephrology, Dokuz Eylül University School of Medicine, Izmir, Turkey.
Acta Diabetol. 2025 May 8. doi: 10.1007/s00592-025-02521-3.
Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease (ESKD) worldwide. Macrophages and the complement system have interrelated roles in DN. We aimed to determine associations between macrophage and complement markers with the progression of DN.
This retrospective cohort study included patients diagnosed with sole DN by kidney biopsy. Using immunohistochemistry, CD68 and CD163 cells and complement markers were counted in glomerular and tubulointerstitial areas. The primary outcome was evolution to ESKD and/or doubling serum creatinine (SCr).
Forty-six patients were included. The median SCr at baseline was 2.7 (1.41-3.1) mg/dL. During the median follow-up of 32 months (range 6-54), 50% of patients reached the primary outcome. Most of the clinical and histological findings were comparable between progressors and non-progressors, while progressors had a higher median number of glomerular CD68+ cells and a higher percentage of glomerulosclerosis. After adjustments for age, sex, and SCr, the median glomerular CD68+ cell number was the sole independent predictor of progression. Glomerular C4d was associated with nephrotic-range proteinuria but not with the progression of kidney failure.
Glomerular CD68+ cell count may serve as a promising predictor of kidney disease progression among patients with DN. Glomerular C4d was associated with nephrotic-range proteinuria but not with the progression of kidney failure.
糖尿病肾病(DN)是全球终末期肾病(ESKD)的主要病因。巨噬细胞和补体系统在DN中具有相互关联的作用。我们旨在确定巨噬细胞和补体标志物与DN进展之间的关联。
这项回顾性队列研究纳入了经肾活检诊断为单纯DN的患者。采用免疫组织化学方法,对肾小球和肾小管间质区域的CD68和CD163细胞以及补体标志物进行计数。主要结局是进展为ESKD和/或血清肌酐(SCr)翻倍。
纳入46例患者。基线时SCr的中位数为2.7(1.41 - 3.1)mg/dL。在中位随访32个月(范围6 - 54个月)期间,50%的患者达到主要结局。进展者和非进展者的大多数临床和组织学结果具有可比性,而进展者的肾小球CD68 +细胞中位数较高,肾小球硬化百分比也较高。在对年龄、性别和SCr进行调整后,肾小球CD68 +细胞中位数是进展的唯一独立预测因素。肾小球C4d与肾病范围蛋白尿相关,但与肾衰竭进展无关。
肾小球CD68 +细胞计数可能是DN患者肾病进展的一个有前景的预测指标。肾小球C4d与肾病范围蛋白尿相关,但与肾衰竭进展无关。